Drug intelligence / Profile preview

batroxase

Development stage: Preclinical
Lead developer: Xijing Hospital
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

Batroxase is a metalloproteinase enzyme isolated from the venom of the *Bothrops atrox* snake. It functions as a direct fibrinolytic and thrombolytic agent by cleaving both the alpha and beta chains of fibrinogen and dissolving fibrin clots, independent of plasminogen activation. This action gives it antithrombotic properties. Batroxase also exhibits weak hemorrhagic activity and can hydrolyze extracellular matrix components such as type IV collagen and fibronectin. Its potential therapeutic applications include the treatment of thrombogenic disorders and the prevention of adhesions.

Targets

COL4 (Collagen IV)Fibrin (Factor Ia)

Beyond the preview

Go deeper on batroxase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on batroxase.

Explore the full profile